A pathophysiological role of PDE3 in allergic airway inflammation

Jan Beute,1 Melanie Lukkes,1 Ewout P. Koekoek,1 Hedwika Nastiti,1 Keerthana Ganesh,1 Marjolein J.W. de Bruijn,1 Steve Hockman,2 Menno van Nimwegen,1 Gert-Jan Braunstahl,3 Louis Boon,4 Bart N. Lambrecht,1,5 Vince C. Manganiello,2 Rudi W. Hendriks,1 and Alex KleinJan1

1Department of Pulmonary Medicine, Erasmus MC, ’s-Gravendijkwal, Rotterdam, Netherlands. 2Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland USA. 3Department of Pulmonology, Franciscus Gasthuis, Rotterdam, Netherlands. 4Epirus Biopharmaceuticals Netherlands Yalelaan, Utrecht, Netherlands. 5VIB Center for Inflammation Research, Ghent University, Ghent, Belgium.

Introduction

Asthma is an obstructive airway disease characterized by inflamed airways, structural and physiological abnormalities of the airways, and shortness of breath (1). Although impressive progress has been made in the treatment of asthma, there still is a significantly high number of uncontrolled severe asthma (2) and asthma deaths worldwide, and consequently a great need for lifesaving therapy (3).

There are 11 isoenzyme families of phosphodiesterases (PDEs). In the context of allergic airway inflammation and asthma, PDE3 and PDE4 are most relevant and widely expressed in airway cells including epithelial cells, endothelial cells, smooth muscle cells, and inflammatory cells (4–9). PDE3 has 2 isoforms (PDE3A and PDE3B) and is a cAMP- and cGMP-specific PDE; PDE4 has 4 isoforms (PDE4A, -B, -C, and -D) and is cAMP specific. PDE4 inhibitors appear to act effectively on immune cells, as well as on endothelial cells, epithelial cells, and airway smooth muscle cells (10). The lack or inhibition of PDE4, an asthma susceptibility gene (11), attenuates airway hyperresponsiveness and airway inflammation in mouse models of allergic airway inflammation (12–18). It is known that genetic variants of PDE4D are associated with asthma (19) and PDE3 inhibition induces smooth muscle cell relaxation with the consequence of bronchodilation (20). Recently, research has focused on the synergy of preparations that combine PDE3- and PDE4-inhibiting effects (21).

Increasing cAMP levels reduces the expression of adhesion molecules and consequently impairs eosinophil and neutrophil adherence to human lung endothelial cells (6). PDE4 isoforms are expressed by both immune cells and structural tissue cells (22), but also in the brain (23), which makes broad-spectrum PDE4 inhibitors like rolumilast less promising as antiasthma drugs in humans (24). When PDE4 inhibitors are dosed according to their advisory dose they may show frequently mild to severe side
effects including diarrhea, headache, and nausea. Even suicides have been reported (25). Presently, no specific PDE4 inhibitor is available for asthma.

Some promising results have been reported for the dual PDE3/4 inhibitor RPL554, which is already in a phase II clinical trial for asthma (21). Although RPL554 is described as a dual inhibitor, it is 3,750-fold more potent for PDE3 compared with PDE4. It has a half-life (t½) of 11 hours (21, 24) and was shown to be effective in an asthma model (7). PDE4 and combined PDE3/4 inhibition may enhance the effects of glucocorticoid treatment (26, 27). Since the major action of RPL554 is PDE3 inhibition, it is important to know what the exact contribution of PDE3 is to allergic airway inflammation. Several lines of evidence support a critical role for PDE3 in cell-cell interactions, including endothelial barrier function and cell junctions (28–31). The data available from PDE3 inhibitors during the 1990s concerned only drugs with a short t½ and failed to show beneficial effects in asthma models, involving long incubation times. At the moment, RPL554 is the only drug available in experimental settings and has not been tested in patients with severe disease. We recently demonstrated beneficial and life-saving effects of the PDE3 inhibitor enoximone in status asthmaticus (32), which were based on enoximone’s known bronchodilatory capacity (20). PDE3 inhibition literature of the 1990s did not show any antiinflammatory effects in animal models of allergic inflammation (33–36). We suggest that this absence of proof may be due to inadequate dosing, a wrong model, and limited use of PDE3 inhibitors. However, clinical data suggest that PDE3 inhibition therapy given via infusion in heart failure, bypass operations, and enterovirus 71 infection did show antiinflammatory effects (37–39).

During the last decade, a growing number of studies suggest that PDE3 inhibition might be involved in immunosuppression (40–48), although there is no definitive proof. There have been concerns that PDE3 inhibitors were associated with increased cardiovascular mortality in previous clinical trials (49, 50). However, a better picture is given by the ESSENTIAL clinical trial (51), where the outcome of the study was that 150 mg oral enoximone per day compared with placebo neither improved advanced heart failure (HF) nor aggravated it, and did not show adverse effects even in heart failure patients.

Based on clinical observations, we wanted to investigate whether PDE3 inhibition might induce an antiinflammatory effect. We investigated the role of PDE3 in an acute house dust mite–driven (HDM-driven) allergic airway inflammation mouse model. We studied the phenotype of PDE3A and PDE3B single-deficient mice. Moreover, we demonstrated the effect of PDE3 inhibition in vivo. Both PDE3 deficiency and pharmacological inhibition of PDE3 activity reduced allergic airway inflammation and improved endothelial barrier function in this asthma model.

**Results**

*High expression of PDE3 and PDE4 in lung mucosal tissue obtained from healthy controls and asthmatic patients.* To begin with, we studied protein and mRNA expression of PDE3 and PDE4 isoforms in the airways and immune cells. PDE3A and PDE3B proteins were detected in the epithelium, endothelium, smooth muscle cells, and inflammatory cells. No differences in PDE3 protein (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.94888DS1) or mRNA expression (Supplemental Figure 1C) were seen in human lung mucosal biopsies with eosinophilic airway inflammation (Supplemental Figure 1D) or murine lung mucosal samples using quantitative PCR (qPCR) (Supplemental Figure 2A). Cultured murine B cells and dendritic cells (DCs) expressed PDE3B (Supplemental Figure 2, B and C). IgM activation of B cells induced increased expression of PDE3B in B cells. HDM activation of DCs reduced PDE3B expression. Naïve and CD4+ T cells differentiated into various Th subsets, expressing high levels of PDE3B, PDE4A, PDE4B, and PDE4D (Supplemental Figure 2D).

We found that although structural lung cells expressed both PDE3A and PDE3B, inflammatory cells expressed mainly the PDE3B isoform and PDE4.

*Absence of PDE3A or PDE3B expression results in a reduced inflammatory response in an HDM-driven allergic airway inflammation model in mice.* Since PDE3 is widely expressed in lung cells, including inflammatory cells, we examined the specific role of PDE3 in allergic airway inflammation. We investigated eosinophilic airway inflammation in 3 subsets of mice: PDE3A–/– mice, PDE3B–/– mice, and WT littermates. We used an HDM-driven model for allergic airway inflammation according to the schedule depicted in Figure 1A. HDM-treated WT mice demonstrated a clear eosinophilic airway inflammation (Figure 1B). The numbers of eosinophils in bronchoalveolar lavage (BAL) fluid were significantly higher in HDM-treated WT mice when compared with PBS-treated control mice (Figure 1C). The eosinophil number was 6-fold higher in WT
mice when compared with \textit{PDE3A}^{−/−} mice and 5-fold higher when compared with the \textit{PDE3B}^{−/−} mice (Figure 1C). Other inflammatory cell counts, including T cells, neutrophils, macrophages, and DCs, followed roughly the same pattern (Figure 1C and Supplemental Figure 2). T cells showed an approximately 3-fold higher number in HDM-treated WT mice when compared with HDM-treated \textit{PDE3A}^{−/−} or \textit{PDE3B}^{−/−} mice.
All findings supported the hypothesis that the absence of either PDE3A or PDE3B activity attenuates eosinophilic airway inflammation in an HDM-driven allergic airway inflammation model in mice.

\textbf{PDE3A–/– and PDE3B–/– mice show a reduced Th2 cytokine response and a decreased level of the proinflammatory cytokine TNF-α.} The presence of eosinophils is indirect proof that a Th2 lymphocyte response to HDM was induced. Because the cellular inflammatory reaction was strongly reduced in \textit{PDE3A–/–} mice and \textit{PDE3B–/–} mice, we investigated whether this reaction was mitigated due to an impaired Th2 response. Indeed, both proportions and cell numbers of IL-5– and IL-13–positive CD4+ T cells in BAL were reduced in HDM-treated \textit{PDE3A–/–} and \textit{PDE3B–/–} mice when compared with HDM-treated WT mice (Figure 2, A and B). As we had been able to demonstrate that both generalized inflammation and Th2-cell cytokine production were less in both types of \textit{PDE3–/–} mice, we also investigated the cytokines produced in the alveolar lumen by BAL fluid analysis. We found lower levels of the proinflammatory cytokine TNF-α and the Th2 cytokine IL-5 in \textit{PDE3A–/–} and \textit{PDE3A–/–} mice when compared with WT mice in our model (Figure 2C).

\textbf{We were not able to demonstrate different keratinocyte-derived protein chemokine (KC) (murine IL-8) levels in HDM-treated WT, \textit{PDE3A–/–}, and \textit{PDE3B–/–} mice, compared with PBS-treated mice.} Cytokine production is an important feature in allergies, so we next investigated cytokine production in vitro. HDM- or PBS-restimulated lung draining mediastinal lymph node (MLN) cells by ELISA. In WT mice MLN cultures, we observed a marked increase of IL-4, IL-5, and IL-13 (Figure 2D), indicating HDM-specific reactivity of MLN cells, most probably CD4+ T cells (Figure 2A). In contrast, MLN cultures from \textit{PDE3A–/–} and \textit{PDE3B–/–} mice showed markedly reduced Th2 cytokine production. On the other hand, IFN-γ was induced in all MLN cultures from WT, \textit{PDE3A–/–} and \textit{PDE3B–/–} mice at similar levels.

\textbf{We concluded that HDM-reactive T helper cells in mice lacking PDE3 produce less Th2 cytokine, while IFN-γ is unaffected.} Moreover, the proinflammatory cytokine cytokine TNF-α, as measured in BAL fluid, is lower in \textit{PDE3–/–} mice, illustrating less pronounced immune activation when compared with WT mice in allergic airway inflammation.

\textbf{PDE3A–/– and PDE3B–/– mice show reduced albumin leakage in an HDM-driven allergic airway inflammation model.} Endothelial cells are an important target of TNF-α, since its proinflammatory effects lead to increased permeability across endothelial cells. The next step in this study was to demonstrate this endothelial permeability by analysis of the leakage of large serum proteins like albumin (52, 53). When endothelial barrier function is impaired, more albumin will leak through the airway’s endothelium into the lung mucosal tissue (edema), which in turn is responsible for additional airway narrowing in asthmatics (54). The PDE3 inhibitor cilostazol has been shown to improve barrier function by reducing leakage of albumin in vitro (55). We studied albumin leakage in both lung tissue and alveolar lumen by ELISA, which is reliable, instead of indirect Evans blue dye techniques (52, 53, 56). Initially, PBS-treated WT, \textit{PDE3A–/–}, and \textit{PDE3B–/–} mice had albumin levels that are within the normal range. This implies that barrier function is unaffected under noninflammatory conditions. When challenged with HDM, WT mice displayed an increase in albumin content, suggesting greater leakage, which was not observed in the \textit{PDE3A–/–} or \textit{PDE3B–/–} mice (Figure 3A).

\textbf{During inflammation, the vasculature leaks proteins because of the large interendothelial cell spaces; as stated above, this leakage causes edema, which in turn causes additional airway narrowing in asthmatics.} To investigate this, lung tissue sections were stained and analyzed for their albumin content (for details see the Methods; for quantification see Figure 3, B and C and representative examples D–L). Albumin intensity was centered primarily on the airway vasculature in PBS-treated mice. Additionally, some albumin staining was seen in bronchial mucus in HDM-treated mice, indicating that during inflammation tissue albumin progresses into the mucus as well. However, most of the direct leakage from the larger blood vessels was observed in the perivascular region (especially clear in the images of Figure 3, D–F). When comparing HDM-treated WT mice (Figure 3, G and J) with \textit{PDE3A–/–} and \textit{PDE3B–/–} mice (Figure 3, H, I, K, and L), the peribronchial region directly surrounding the bronchioles appeared less albumin-infused in the \textit{PDE3A–/–} and \textit{PDE3B–/–} HDM-treated mice. When looking more closely at the peribronchial region (selections highlighted in white in Figure 3, J–L) it becomes apparent that in WT mice (Figure 3J) the small vasculature surrounding the bronchioles (highlighted with white arrows) was much more intensely stained for albumin when compared with the \textit{PDE3A–/–} and \textit{PDE3B–/–} mice (Figure 3, K and L). Compared with WT mice, HDM-treated \textit{PDE3A–/–} mice displayed a significantly reduced increase of albumin content in both peribronchial and perivascular leakage, whereas HDM-treated \textit{PDE3B–/–} mice only significantly differed from the WT HDM-treated animals in terms of peribronchial leakage. No marked differences were observed between the groups of PBS-treated mice, indicating that no albumin leakage occurred.
Figure 2. PDE3–/– mice showed diminished Th2 cytokine in HDM-restimulated MLN cell suspension and BAL fluids. (A) Intracellular cytokine expression profiles (proportion and numbers) of gated bronchoalveolar lavage (BAL) CD3+CD4+ T cells upon 4 hours of PMA/ionomycin stimulation. (B) Quantification of flow cytometric analyses of the indicated populations of BAL CD3+CD4+ T cells. (C) BAL fluids were assayed with ELISA for indicated cytokines. (D) Single-cell suspensions of mediastinal lymph node (MLN) cells were restimulated with 1 μg/ml house dust mite (HDM) for 7 days and supernatants were assayed with ELISA for indicated cytokines. Kruskal-Wallis test for multiple comparisons was used followed by Mann-Whitney U test. Data represent 2 separate experiments (n = 3 for all PBS groups, n = 7 for WT HDM, n = 5 for both PDE3A–/– and PDE3B–/– HDM groups) and are shown as the mean ± SEM. *P < 0.05, **P < 0.01.
In summary, the findings in these tests demonstrate that PDE3−/− mice had less vascular albumin leakage, indicating an improved barrier function under inflammatory conditions when compared with WT mice. *PDE3 inhibition attenuates allergic airway inflammation.* Because lack of PDE3 activity improved the cardinal pathophysiological manifestations of asthma including airway inflammation and edema formation, we...
proceeded by targeting PDE3 in a therapeutic intervention using a PDE3 inhibitor. Successful off-label use of the PDE3 inhibitor enoximone was described in the context of status asthmaticus (32). Next to its PDE3 inhibitory properties (IC50 = 5.9 μM), enoximone also exhibits some PDE4 inhibitory effect, more specifically a myocardial PDE4A inhibitory effect (IC50 = 21.1 μM) (57, 58). Cardiomyocytes express mainly PDE4A1A (59).

We used an HDM-driven mouse model for allergic airway inflammation according to the schedule depicted in Figure 4A, with enoximone or diluent given via the intratracheal route. A significant reduction of airway inflammation was seen in mice treated with optimal doses of enoximone (Figure 4, B–D and Supplemental Figure 4).

From these experiments, we concluded that targeting PDE3 — particularly during allergen challenge — prevents HDM-driven airway inflammation. Similar results were seen when enoximone was given via the oral route (Supplemental Figure 3).

Treatment with a PDE3 inhibitor reduces eosinophilia during ongoing allergic inflammation. We next investigated if PDE3 inhibition with enoximone is capable of attenuating airway inflammation in already established allergic airway inflammation. Prospectively, we created 3 different groups of WT mice (Figure 5A). One group consisted of PBS/diluent controls only. Two other groups were sensitized with HDM, followed by 5 additional HDM challenges on days 10–14 thereafter. Mice with allergic airway inflammation were then challenged again on 5 successive days (days 15–19) with HDM admixed (given simultaneously) with diluent...
or enoximone (Figure 5A). At day 20, the controls showed no signs of allergic inflammation in the BAL. The diluent-treated HDM-exposed mice showed significantly increased levels of eosinophils, macrophages, group 2 innate lymphoid cells (ILC2s), and T cells, indicating an allergic reaction (Figure 5B). The enoximone-treated HDM-exposed mice showed significant reductions in inflammatory cell numbers including eosinophils, macrophages, ILC2s, and T cells, indicating that enoximone treatment reduced airway inflammation (Figure 5B). Induction of neutrophils was limited, but their numbers also tended to be lower in enoximone-treated mice compared with diluent-treated mice. We also investigated the numbers of Th2 cytokine–producing T cells and observed a significant reduction in IL-13–positive CD4+ T cells and IL-5–positive CD4+ T cells tended to be lower, while IFN-γ– and IL-17–producing T cells remained the same (Figure 5C).

These data showed that the PDE3 inhibitor enoximone substantially reduces established Th2-driven allergic airway inflammation in an HDM-driven asthma mouse model.

Milrinone, a PDE3 inhibitor with a short t½, showed an antiinflammatory effect. To confirm our enoximone data, another clinically available PDE3 inhibitor, milrinone, was investigated. Milrinone is a 5-fold more potent PDE3 inhibitor than enoximone (IC50 1.2 and 5.9 μmol/l, respectively) (57). It has a shorter t½
than enoximone (<2 hours vs. 7 hours, respectively). We performed a dose-response and timing variation study (Figure 6A) and observed that treatment with 10 μg milrinone intratracheally (i.t.) is as potent as 25 μg enoximone i.t. in reducing eosinophilic airway inflammation when given during challenge (Figure 6B). In addition, one group received 1 μg milrinone 2 hours before sacrificing (Figure 6A). In this group, a reduction was observed in eosinophilic airway inflammation (Figure 6B).

From these experiments, we concluded that targeting PDE3 with optimal doses and timing, milrinone also prevents HDM-driven allergic airway inflammation.

PDE3 inhibition and the expression of CD11b. Given the fast antiallergic response, we investigated whether PDE3 effects on integrin might be associated in allergic airway inflammation. Mouse and human eosinophils express CD11b, an integrin that is crucial for immune cell extravasation (60). Elevated levels of CD11b in neutrophils and eosinophils were seen in affected lung tissue when compared with blood levels (61). Segmental lung antigen challenge upregulates and activates eosinophil integrins in blood and airways of asthmatics (62). From studies in the 1990s it is known that PDE4 inhibition and theophylline can rapidly reduce the expression of CD11b in neutrophils and eosinophils (63, 64). BAL eosinophils and neutrophils showed no differences in CD11b phenotype when they were obtained from mice lacking PDE3A or PDE3B or WT (Figure 7, A and B). BAL alveolar macrophages expressed lower levels of CD11b when they were obtained from PBS- or HDM-treated mice lacking PDE3A or PDE3B when compared with PBS- or HDM-treated WT mice (Figure 7C). In vitro, 10 μM enoximone–treated BAL eosinophils induced by IL-33 treatment (65) showed significantly lower CD11b expression when compared with diluent-treated BAL eosinophils (Figure 7D).

Peripheral blood mononuclear cells (PBMCs) obtained from buffy coats were pretreated with either diluent or enoximone and activated with platelet activation factor (PAF), N-formylmethionyl-leucyl-phenylalanine (fMLP), or diluent. PAF and fMLP induced the expression of CD11b in eosinophils (Figure 7E). Lower CD11b expression was observed in ex vivo samples pretreated with enoximone and stimulated with PAF or fMLP (Figure 7, F and G) when compared with diluent (n = 6). CD11b mean fluorescence
intensity (MFI) reduction due to enoximone compared with diluent control treatment was seen in unstimulated, fMLP-, or PAF-stimulated samples (summarized in Figure 7H). These findings imply that decreasing CD11b expression is one of the antiinflammatory targeting mechanisms of enoximone with similar characteristics to PDE4 inhibitors.

Discussion
In our study, we provide evidence that PDE3 plays a pathophysiological role in allergic airway inflammation. In particular, we demonstrated in a physiologically relevant model that HDM-driven allergic inflammation is reduced by targeting PDE3, employing PDE3A- or PDE3B-knockout mice, or by pharmacological inhibition. This reduction was observed when pharmacological intervention was given orally, or topically by means of admixing enoximone with HDM solution followed by intratracheal administration. Hereby, enoximone was also effective when administered to mice with established disease. This potentially novel antiinflammatory observation indicates that besides targeting PDE4 to reduce allergic airway inflammation (18, 66), targeting the related enzyme PDE3 also substantially reduces allergic airway inflammation.

The BAL fluid of both PDE3A−/− and PDE3B−/− mice consequently contained significantly lower numbers of inflammatory cells, including eosinophils, as well as less cytokines, when compared with the WT controls. T cell functionality was also affected, as demonstrated by a reduced ability of HDM-restimulated MLN cells to produce and secrete inflammatory cytokines. An important aspect is that the endothelial

![Figure 7. PDE3 activity influences the CD11b expression in eosinophils, neutrophils, and alveolar macrophages.](image)
barrier function, which is severely hampered in WT mice following treatment with HDM, was preserved in PDE3A−/− or PDE3B−/− mice. We observed the mechanisms, but the molecular delineation into the mode of action of PDE3 isoforms in allergic airways disease remains to be clarified.

Inhibition of PDE3 and elevation of cAMP improved epithelial and endothelial barrier function and reduced smooth muscle cell proliferation, which represent important therapeutic effects in the context of asthma treatment (5). Both PDE3 and PDE4 play a key role in regulating cAMP-induced signalling. Levels of intracellular cAMP are important for the type of immune response and affect Th1 and Th2 responses, whereby increased levels of cAMP were found to cause bronchodilation (67). Genome-wide studies in asthma identified an association with a PDE4D polymorphism that is linked to hyperactive PDE4. This polymorphism causes low intracellular levels of cAMP in smooth muscle cells, which is associated with decreased forced exhaled volume in 1 second (FEV1) and bronchial hyperreactivity (11, 14, 68).

The side effects of treatment with PDE4 inhibitors may be quite severe, physically as well as mentally; even suicides have been reported (24, 69). PDE4 inhibitors are rarely prescribed nowadays, owing to these side effects. On the other hand, clinical observations indicate immediate bronchodilation in asthma patients (8, 36, 70) and in status asthmaticus patients when treated with the PDE3 inhibitor enoximone (32). We would like to underline that the dosage of PDE3 inhibitor enoximone used in early studies that resulted in cardiovascular mortality was very high, 10- to 100-fold higher (up to 2,400 mg) than the dosage used in our case report study (ref. 32 and J. Beute unpublished data). Long-term use of high-dose PDE3 inhibitors is not suitable for heart failure patients (71). PDE3 inhibitor therapy is currently only used in heart failure patients to bridge the period to cardiac transplant and in the ICU to prevent organ failure.

This study shows that a low dose of a not very potent (IC50 5.9 μM) PDE3 inhibitor is able to counteract allergic reactions, thereby avoiding severe consequences that may result from potent PDE4 inhibitors or high doses of PDE3 inhibitor. Our model is suitable to study acute allergic inflammation. Studies are underway to investigate the role of PDE3 in airway hyperresponsiveness in a chronic HDM-driven asthma model (A. KleinJan, manuscripts in preparation). The importance of drug t½ is illustrated by the results of the comparison between milrinone (t½ < 2 hours) and enoximone (t½ = 7 hours). The t½ is an important feature of effectiveness in allergic airway inflammation (Figure 6B), but at the same time it is not directly proportional to the effective duration of the drug action. The difference might spring from the metabolite of enoximone being bioactive versus the inactive metabolite of milrinone (72). Earlier studies showed no antiallergic properties; however, the time in between drug administration moments was 24 hours and substantially longer than its t½, and the effect may have waned during incubation. Milrinone may be as effective as enoximone, showing an effect when given in a low dose 2 hours before sampling the mice, but it has to be kept in mind that the t½ of milrinone in healthy subjects is probably less than 2 hours. This is a good feature for an intravenously administered drug (milrinone and enoximone presently are administered in an ICU setting in the treatment of circulatory failure), but not for an oral drug that requires limited administration.

Our mouse data support the clinical observation of the beneficial use of enoximone in the treatment of allergic asthma and show an antiinflammatory effect. The exact mechanism underlying the antiinflammatory effects of enoximone have not yet been elucidated. PDE4 inhibition has a direct effect on the expression of CD11b on eosinophils; this is also seen when applying enoximone. Evidence has shown that CD11b expression is also reduced by PDE3 mutants and by PDE3 inhibition as a stand-alone agent. When PBMCs were treated with enoximone, the cells could not be activated by PAF or fMLP. There is no difference in the expression level of CD11b on eosinophils in either blood or in induced sputum between healthy controls and asthmatic patients. Although CD11b levels on eosinophils were higher in sputum than in blood, indicating that CD11b expression is location dependent and is the highest at the site of inflammation (61), analysis of BAL eosinophils from enoximone- or diluent-treated HDM-challenged mice did not show any differences in CD11b expression, which is in line with human data from in’t Veen et al. (61). They also found the highest CD11b expression in the alveolar compartment, irrespective of having asthma or being healthy (61). A reduction in CD11b prevented extravasation of the CD11b-expressing cells, keeping these cells in the circulation and preventing them from injuring the diseased organ. It has been established that eosinophils can be seen in the pulmonary lymph nodes in asthmatic mice (73). Therapeutic CD11b reduction enables the eosinophils to disappear via the lymphatic system or via cough and swallow and prevent extravasation from the circulation. The rapid reduction in CD11b expression in neutrophils and eosinophils due to PDE3 inhibition might be an explanation for why inflammatory cells rapidly disappear when the airways were treated with the PDE3 inhibitors.
The anti-inflammatory effects of enoximone have been established in other studies and are illustrated by reduced serum TNF-α levels during PDE3 inhibition, compared with dobutamine-treated septic patients (38). In alveolar epithelial cells, LPS-induced biosynthesis of proinflammatory cytokines is regulated by cAMP and tightly controlled by PDEs, and can be reduced by PDE inhibitors (74). Reduction in eosinophilic inflammation resulted in reduced exposure to peroxidase and peroxide and reactive oxygen species (75, 76). When endothelial cells were exposed to peroxide or other active oxides, permeability of endothelial cells increased, leading to leakage (77, 78).

We showed reduced endothelial albumin leakage, as measured by lower concentrations of albumin in BAL fluid or tissue in mice lacking PDE3, or as measured in WT mice treated with a PDE3 inhibitor. We decided to measure the albumin content directly in BAL fluid and not via the indirect method of Evans blue dye (52, 56). By measuring albumin in lavage or in tissue, we could clearly see a close correlation between inflammation and albumin concentration. Experimental lung edema and clinical lung edema can evidently be attenuated by selective PDE3 inhibition (44) and/or PDE4 inhibition (39, 44, 78–80).

Enoximone has the advantage that a low dose is already biologically active and has been in clinical use for more than 20 years. Theophylline relaxes human airway smooth muscle cells by inhibiting PDE3 (81). In this context it is of note that theophylline has a nonselective PDE inhibitory activity and only a modest degree of bronchodilatory activity, including antiinflammatory and immunomodulatory activity (81). Using low doses of clinically available PDE3 inhibitory drugs such as enoximone or milrinone, it is possible to bypass the serious side effects that were often seen when asthma patients were treated with the very potent PDE4 inhibitors.

In conclusion: (a) we demonstrated the presence of PDE3 protein and mRNA in human and murine airway tissues, (b) we proved that PDE3 inhibition is an important therapeutic target in the context of allergic airway inflammation, and (c) we concluded that PDE3A or PDE3B deficiency or the inhibition of PDE3 may alleviate the symptoms of allergic airway inflammation. PDE3 inhibitors including enoximone and milrinone are already on the market and in off-label use for other indications, such as pulmonary artery hypertension (PAH) in children (in the UK). Because our study strongly supports the conclusion that targeting PDE3 in allergic airway inflammation may be a novel effective treatment strategy, further research is essential and desirable.

Methods

Patients for human bronchial biopsies. Patients that met the criteria for asthma, were nonsmoking mild asthmatics, with an FEV1 greater than 60% predicted (or more than 1.5 liters because of safety aspects), greater than 10% improvement of FEV1 after maximal bronchodilation and/or increased bronchial hyperresponsiveness (i.e., PC20 methacholine < 8 mg/ml), in a stable clinical condition, and sensitized for at least HDM (skin prick test) were enrolled in the study. Healthy controls showed no signs of sensitization and were not hyperreactive.

Animals. PDE3A−/− and PDE3B−/− C57BL/6 mice were previously described (82, 83) and showed no abnormalities regarding T cell development (data not shown). WT C57BL/6 mice were purchased from Envigo. Animals were kept under specific pathogen-free conditions, provided with water and food ad libitum, and were used at the age of 6–12 weeks.

HDM allergic airway inflammation model. To induce airway inflammation, mice were anaesthetized with isofluorane and treated i.t. with 10 μg (or as indicated) HDM (Greer Laboratories) allergen extract in 50 μl PBS on day 0 or using PBS only (84). Ten days later, anaesthetized mice were challenged with 10 μg or 0 μg HDM in 50 μl PBS intranasally (i.n.) for 5 consecutive days. Mice were sacrificed 24 hours after the last challenge and BAL was performed by flushing the lungs 3 times with 1 ml PBS containing ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich) (Figure 2A).

Route of treatment, oral and intratracheal doses. Measurements were performed 24 hours after the last challenge.

Optimal dose of 25 μg enoximone versus diluent (Figure 5) was administered with 5 μg HDM solution and used for intratracheal treatment, or diluent (10% ethanol + 40% glycerol + 50% Milli-Q water, pH 12) was administered with 5 μg HDM solution. Controls were treated with 25 μg enoximone administered with PBS or diluent administered with PBS. Mice underwent enoximone treatment only during challenge.

Treatment strategy 2: established HDM allergy model. C57BL/6 mice were sensitized with 10 μg HDM on day 0 and challenged with 5 μg HDM for 5 days on days 10–14. Subsequently, the mice were treated with 5 μg HDM admixed with 25 μg enoximone or diluent for 5 days on days 15–19. The controls received only PBS (diluent). Twenty-four hours after the last challenge, all animals were sacrificed and sampled.
**Immunohistochemical staining.** Stainings were performed in a half-automatic stainer (Sequenza). Acetone-fixed slides were washed with PBS and incubated and blocked in diluted normal goat serum or normal rabbit serum (CLB). Sections were stained with mouse anti-human PDE3A (clone 2D7, Abnova), mouse anti-human PDE3B (clone F-9, Santa Cruz Biotechnology), or rabbit anti-human PDE4 (Fabgenix, catalog PD4-101AP). The primary antibody was detected using goat anti-mouse long-chain biotin-streptavidin conjugated to alkaline phosphatase (BioGenex), goat anti-rabbit conjugated to alkaline phosphatase (Sigma-Aldrich), or goat anti-PE conjugated to alkaline phosphatase (Rockland, 600-105-387) and rabbit anti-goat conjugated to alkaline phosphatase. After rinsing, slides were incubated with New Fuchsin substrate (Sigma-Aldrich). Some slides were stained with goat anti-albumin horseradish peroxidase (HRP) (Bethyl Laboratories, A90-134P) and incubated with Nova Red substrate (Vector). Finally, the sections were counterstained with Gills triple-strength hematoxylin (Sigma-Aldrich) and mounted in VectaMount (Vector). Eosinophils were stained with antibodies against Siglec F (BD Biosciences, 552126) to identify eosinophilic airway inflammation.

**Albumin quantification in lung mucosal sections.** Albumin quantification was done by taking a representative image from each section and assigning it an ID. These images were then ranked in a blinded fashion (EPK and AKJ) from most to least stained in terms of leakage either peribronchially or perivascularly. Once arranged, the IDs were used to relate which image belonged to which animal. This resulted in an arbitrary rank score to quantify the albumin leakage (Figure 3, K and L).

**Analysis of PDE expression.** RNA was isolated from patient lung biopsies and mouse whole tissue using a Total RNA Purification Kit (Sigma-Aldrich). Purity of the extracted RNA was verified using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). From the RNA, cDNA was reverse transcribed using a RevertAid First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific). qPCR primers (for detailed description of primer sequences see Supplemental Tables 1 and 2) specific for all PDE3 and -4 isoforms were designed, using a universal probe library (Roche Diagnostics), and checked for efficiency. Using SYBR Select Master Mix (Applied Biosystems), the cDNA was analyzed via qPCR, using a 7300 Real-Time PCR System (Applied Biosystems). Resulting data were normalized to relative expression of household genes (β-actin in human and hypoxanthine-guanine phosphoribosyl transferase [HPRT] in mouse). Resulting data were further analyzed using the comparative Ct (2^{-ΔΔCt}) method (85).

**Flow cytometric analysis.** BAL, lung cells, and MLN cells were collected for cellular differentiation by flow cytometry as previously described (84). Eosinophils were identified as cells within the granulocyte gate and positive for Siglec F. T cells were identified as cells in the lymphocyte gate and positive for CD3. DCs were identified as cells in the lymphocyte gate and positive for CD11c and MHCII. In some experiments, a fraction of the isolated cells was stimulated with ionomycin (Sigma-Aldrich), phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich), and GolgiPlug (BD Biosciences) at 37°C for 4 hours. Then, cells were stained for CD3, CD4, and intracellularly for IL-4, IL-5, IL-13, IL-17, and IFN-γ, after fixation with 2% paraformaldehyde and permeabilization using a saponin-containing buffer. Fixable Aqua Live/Dead for 405 nm (Invitrogen, Molecular Probes) was used to distinguish between live and dead cells (84). Cells were analyzed using an LSRII flow cytometer (BD Biosciences) and FlowJo software (Tree Star Inc.).

**PDE inhibition of eosinophils.** PBMCs were isolated fromuffy coats of healthy blood donors (n = 6) by lysing the red blood cells with lysis buffer (NH₄Cl) and washed with RPMI twice. Then, the cells were incubated with enoximone, rolipram diluent, and PBS for 30 minutes at 37°C, and next stimulated with PAF (Sigma-Aldrich), fMLP (Sigma-Aldrich), or diluent for 1 hour and washed and stained with Siglec F (Biolegend, 7C9) for eosinophils and markers for non-eosinophils, CD15PE-CF594 (BD Biosciences, W6D3), CD14PE-CF594 (eBioscience, 61D3), and CD3APC (eBioscience, UCHT1). DAPI or Aqua Live/Dead was used to distinguish between live and dead cells. Based on forward scatter (FSC) and side scatter (SSC) to identify the granulocyte population, eosinophils were selected and CD11b (ICRF44) expression was evaluated on live eosinophils. Treatment of cells was performed with 1 μM PAF and 10 μM fMLP and diluent (10% ethanol + 40% glycerol + 50% Milli-Q water). 25 μg/ml enoximone.

**Statistics.** Reported values are shown as the mean ± SEM. Statistical analyses were performed with SPSS (SPSS Inc.) using Kruskal–Wallis 1-way ANOVA followed by Mann-Whitney U test. Mann-Whitney U test was only performed if the 1-way ANOVA test pointed to significance and the Sign test for paired samples. Resulting P values less than 0.05 (*) and 0.01 (**) are indicated and considered significant. Tests that did not reach significance (P > 0.05) are not indicated.
Study approval. All participants provided informed written consent, which was approved by the medical ethics committee of the Erasmus Medical Center, Rotterdam, The Netherlands. Data from these patients were previously described (86, 87); detailed descriptions of the characterizations of the bronchial mucosa biopsies obtained from asthmatics showed more eosinophils than those obtained from healthy controls — see Supplemental Figure 1E. Peripheral blood cells were isolated from buffy coats of blood donors (Sanquin Bloedvoorziening, NVT nr. 0014.03, Rotterdam, The Netherlands). All animal experiments were approved by the Erasmus MC Animal Ethics Committee.

Author contributions
JB and AK contributed to study design and wrote and edited the manuscript. ML, EPK, KG, HN, MJWB, MVN, AK, and BNL contributed to performing the studies and obtaining the samples analyzed in this study. SH, VCM, GJB, LB, BNL., and RWH were involved in reviewing and shaping the manuscript. All approved the final version before submission.

Acknowledgments
This study is supported by Stichting Astma Bestrijding. Vincent Manganiello sadly died prior to completion of the manuscript. Vincent Manganiello and Steven Hockman were supported by the intramural research program NIH/NHLBI. Joel Moss, a long-time NHLBI colleague of Vincent Manganiello, assumed responsibility for its content.

Address correspondence to: Alex KleinJan, Department of Pulmonary Medicine, Erasmus MC, ’s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. Phone: 31.10.704.3698; Email: a.kleinjan@erasmusmc.nl.

20. Leeman M, Lejeune P, Melot C, Naeije R. Reduction in pulmonary hypertension and in airway resistances by enoximone...
(MDL 17,043) in decompensated COPD. *Chest*. 1997;91(5):662–666.
81. Barnes PJ. Theophylline.
74. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selec-